Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington's Disease

Contributed by: PR Newswire

Tags

Skyhawk-HREC

More Like This

PR Newswire associated0

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

PR Newswire associated0

Skyhawk Therapeutics Presents at Huntington's Disease Youth Organization HDYO International Congress 2025

PR Newswire associated0

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

PR Newswire associated0

Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location

HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data

PR Newswire associated0

HUIDAGENE THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN MULTINATIONAL PHASE 1/2 TRIAL OF HG004 FOR INHERITED BLINDNESS

MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference

EQT Life Sciences leads USD 75 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington's disease